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Resolution via chiral HPLCAbstract A synthesis of (±)-thia-calanolide A 3 has been successfully accomplished starting from
3,5-dimethoxythiophenol 4, in six steps in an overall yield of 4.5%. The key reaction involved
Friedel–Crafts tigloylation of 5,7-dihydroxy-4-n-propyl thiocoumarin 6 employing an appropriate
solvent of CS2–PhNO2 in a ratio of 7:3. In its biological evaluation for anti-HIV activity,
(±)-thia-calanolide A 3 demonstrated comparatively less activity with calanolide A and its
synthetic analogue aza-calanolide. Further, (±)-3 has been resolved by chiral HPLC to (+) and
()-3.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
(+)-Calanolide A [(+)-1], non-nucleoside reverse transcriptase
inhibitor (NNRTI) and few new coumarin derivatives isolated
from Calophyllum langerum (Kashman et al., 1992) which
showed promising activity towards human immunodeﬁciency
virus (HIV-1) reverse transcriptase (Currens et al., 1996a,b).It is also active against many strains ofMycobacterium tubercu-
losis including those resistant to the standard antitubercular
drugs (Xu et al., 2004) and is reported through molecular
dynamics simulation of SARS-CoV to be a potent proteinase
inhibitor (Lee et al., 2003). Calanolide A is in clinical testing
phase II as anti-HIV drug; (Buckheit et al., 2000; Cragg and
Newman, 2003) interest therefore arose particularly in develop-
ing its analogues. So far, most of the analogues were either less
potent or devoid of any anti-HIV activity (Galinis et al., 1996;
Zhou et al., 1999; Zembower et al., 1997; Xu et al., 1998; New-
man et al., 1998); however, aza-calanolide A [(±)-2] (Sharma
et al., 2003) exhibited enhanced in vitro anti-HIV reverse trans-
criptase activity. These ﬁndings prompted us to undertake the
total synthesis of thia-calanolide A 3 by replacing oxygen in
ring B with a sulphur atom, which might exhibit better activity.
Herein, we describe the ﬁrst synthesis, optical resolution and
in vitro biological evaluation of (±)thia-calanolide A 3 (Fig. 1).
O O
O
O
OH
(+)-calanolide A [(+)-1]
O X
O
O
OH
X = NH : (±)-aza-calanolide A [(±)-2]
X = S : (±)-thia-calanolide A [(±)-3]
BA
D
C
Figure 1 Structure of 1, 2, 3.
S
OMe
HO O
O
S
OMe
O O
O
S
OMe
MeO O
5
8
9
K2CO3,
reflux,1.5 h
tigloyl chloride, AlCl3
CS2:PhNO2 (1:1)
50 °C, 48 h
70%
2-butanone
73%
Scheme 2
S1598 A.U. Chopade et al.2. Results and discussion
Thiophenol 4, obtained from phloroglucinol (Wolfers et al.,
1975) or from 3,5-dimethoxyaniline by diazotization followed
by reaction with Na2S + S or NaSH (Allen and Mackay,
1943) was subjected to Pechmann condensation with ethylbu-
tyrylacetate in presence of sulphuric acid (Sethna and Phadke,
1953). However, it yielded the undesired 7-hydroxy-5-meth-
oxy-2-propyl-4H-thiochromen-4-one. The required 5,7-dime-
thoxy-4-propyl-2H-thiochromen-2-one 5 was obtained by a
modiﬁed Pechmann method where triﬂic acid was used instead
of H2SO4. Demethylation with AlCl3 yielded 5,7-dihydroxy-
thiocoumarin 6. Friedel–Crafts acylation (Olah, 1964) of 6
with tigloyl chloride yielded a 3:1 mixture of 5,7-ditigloyloxy
thiocoumarin 7a and 5-hydroxy-7-tigloyloxy thiocoumarin 7b
instead of the required C-8 tigloyl coumarin 7 (Scheme 1).
In an alternate route (Sekino et al., 2004) thiocoumarin 5
was subjected to Friedel–Crafts reaction with tigloylchloride
to yield 5-methoxy-7-hydroxy-8-tigloylthiacoumarin 8. Intra-
molecular oxo-Michael addition (IMA) of the latter furnished
the chromanone 9. Subsequent demethylation of 9 with vari-
ous reagents like BBr3/CH2Cl2 at 70 C (Vickery et al.,
1979), BBr3-SMe2/CH2Cl2 (Williard and Fryhle, 1980), BF3-
Et2O/CH2Cl2 (Preston et al., 1983), AlCl3/PhCl at 120 C
(Chenera et al., 1993), and MgI2/K2CO3/PhH (Sekino et al.,
2004) under reﬂux for 15 days did not proceed satisfactorily
to yield the expected demethylated product. With BBr3/
CH2Cl2, compound 8 was regenerated, whereas the startingOMe
SHMeO
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Schemethiocoumarin 9 was recovered unchanged with other reagents
(Scheme 2).
Successful tigloylation was achieved via Friedel–Crafts
reaction from compound 6 employing an appropriate solvent
in a ratio CS2–PhNO2 (7:3). The product 7 thus formed was
cyclized with K2CO3 yielded the desired 8,9-dimethyldihydro-
thiopyranones 10 as an 1:1 epimeric mixture. The required ‘C’
ring was constructed from 10 by reaction with 3-chloro-3-
methyl-1-butyne to yield chromene-chromanone–thiacouma-
rins 11 and 12 in a 1.8:1 ratio and in an overall yield of 34%
(Scheme 3).
Both the ketones 11 and 12 were separately reduced with
NaBH4 to afford (±)-3 and (±)-thia-calanolide C 14 in
44% and 71% yields, respectively. Reduction of 11 with
NaBH4–CeCl3 under Luche condition resulted in a 3:2 mixture
of (±)-3 and (±)-thia-calanolide B (±)-13, respectively
(Scheme 4).
For the ﬁrst time, in the calanolide series, especially in the
thia-calanolide A synthesis, application of HPLC method for
determination and separation of small quantities of the inter-
mediates in the total synthesis of (+)-thia-calanolide has been
developed. Resolution of a mixture of cis and trans of 10 was
found to be excellent using Bondapak silica porasil 30 cm
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cel (OD), 9:1 hexane–isopropanol, 1 mL/min) to afford the
two isomers (+)-3 and (–)-3 having optical rotation
[a]D + 54.3 (c 0.5, CHCl3) and [a]D 49.8 (c 0.3, CHCl3),
respectively (Scheme 5).2.1. Anti-HIV activity assays
Compound (±)-3 was evaluated for anti-HIV reverse
transcriptase activity by following HIV-1 p24 antigen capture
ELISA (Perkin Elmer NEN) as per manufacturer’s protocol.
Brieﬂy, CEM cells were infected with HIV-1 NL4.3 isolate for
4 h in presence of Poltbrene in complete medium. The infected
cells were kept for 7–10 days in culture before the supernatant
was used for HIV-1 p24 antigen capture. The percentage inhibi-
tion of virus production was calculated based on p24 values of
untreated control. (±)-3 was found to be 28% inhibitory as
compared to synthetic (±)-1 which was found to exhibit
99.7% inhibition of virus production.3. Conclusion
The ﬁrst synthesis of (±)-thia-calanolide 3 has been success-
fully accomplished. It has also been resolved by chiral HPLC
to the (+) and () enantiomers which have been fully charac-
terized. Biological evaluation for anti-HIV activity revealed
that 3 is not as achieved as the natural calanolide A and its
synthetic analogue aza-calanolide A. The amphoteric and
S1600 A.U. Chopade et al.bulkier nature of sulphur in 3 could be one of the reasons for
diminished activity.
4. Experimental section
4.1. General
NMR spectra were recorded on a Bruker MSL-300 spectrom-
eter operation at 300 MHz for 1H and 75 MHz for 13C and
Bruker AV-200 spectrometer operation at 200 MHz for 1H
and 50 MHz for 13C. Spectra were obtained at 25 C in CDCl3,
DMSO-d6 and Acetone-d6 solution and were referenced to the
CHCl3 peak (d 7.26), DMSO (d 2.50) for
1H or to the center
line of the CDCl3, DMSO-d6, acetone-d6 at d 77, 39.70, 29.8,
respectively, for 13C, all chemical shifts are given as d values
(in ppm) relative to TMS. IR spectra were recorded on Per-
kin-Elmer FT IR instrument. Optical rotations were measured
as CHCl3 solution using Jasco P-1020 digital polarimeter.
Microanalyses were performed on a Flash EA-1112 Thermo
Finnigan Elemental Analyser. Chiral HPLC was performed
on a SHIMADZU Class-VP using a Chiracel OD column.
Melting points were determined by using a Yanco Micro Melt-
ing point apparatus and were uncorrected.
Reactions with moisture-sensitive chemicals were per-
formed under nitrogen in ﬂame-dried reaction ﬂasks. Solvents
were dried by standard methods. Column chromatography
was carried out using 60–80 mesh and 230–400 mesh silica
gel. Phloroglucinol, dimethylthiocarbamoyl chloride, triﬂuoro-
methanesulfonic acid, ethyl butyrylacetate, tiglic acid, 3-
chloro-3-methyl-1-butyne were purchased from Aldrich and
were used without puriﬁcation.
4.1.1. 5,7-Dimethoxy-4-n-propyl-2H-thiochromen-2-one (5)
A mixture of 4 (0.540 g, 3.17 mmol) and ethylbutyrylacetate
(0.527 g, 3.3 mmol) was added dropwise to cold (5 C) triﬂuo-
romethanesulfonic acid (0.55 mL, 6.34 mmol) over a 10 min
period and the reaction mixture was warmed to 25 C and stir-
red for 17 h. After quenching with ice water (10 mL), the mix-
ture was extracted with EtOAc (3 · 10 mL). The combined
organic layer was washed with brine (2 · 10 mL), dried
(Na2SO4) and concentrated. The residue was subjected to
chromatographic puriﬁcation (EtOAc–pet-ether, 2:8) to give
5 as lemon yellow crystals (0.301 g, 36%). Mp 110–112 C,
IR (CHCl3) 3016, 2965, 1630, 1593 cm
1; 1H NMR
(300 MHz, CDCl3) d 0.97 (t, J= 7.3 Hz, 3H), 1.58 (m, 2H),
2.90 (t, J= 7.3 Hz, 2H), 3.82 (s, 3H), 3.86 (s, 3H), 6.20 (s,
1H), 6.37 (d, J = 2.5 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H). 13C
NMR (75 MHz, CDCl3) d 14.1, 24.0, 41.8, 55.5, 55.6, 98.2,
101.8, 111.5, 122.7, 142.4, 156.9, 160.7, 160.8, 184.1. Anal.
Calcd for C14H16O3S: C, 63.61; H, 6.10; S, 12.13. Found: C,
63.61; H, 6.21; S, 11.07.
4.1.2. 5,7-Dihydroxy-4-n-propyl-2H-thiochromen-2-one (6)
To a stirred solution of 5 (1 g, 3.78 mmol) in chlorobenzene
(10 mL) was added AlCl3 (2.5 g, 1.89 mmol) in portions over
a period of 15 min and the reaction mixture was heated to
100 C under stirring for 12 h. The mixture was then cooled
to room temperature and poured on crushed ice (20 g) and stir-
red well for 30 min. The solid precipitated was ﬁltered, washed
with water (50 mL) till neutral, then washed with hexane
(5 mL) and dried in vacuum to give 6 (0.849 g, 95%) as a darkbrown solid. Mp 230–235 C (decomp.): IR (CHCl3) 3159,
1600 cm1; 1H NMR (300 MHz, CDCl3 + DMSO-d6) d 0.95
(t, J= 7.3 Hz, 3H), 1.60 (m, 2H), 2.97 (t, J= 7.3 Hz, 2H),
6.04 (s, 1H), 6.39 (s, 2H), 9.70 (s, 1H), 10.02 (s, 1H); 13C
NMR (75 MHz, DMSO-d6) d 14.0, 24.0, 40.7, 102.6, 104.4,
108.2, 120.3, 140.9, 158.1, 159.7, 159.9, 182.6; Anal. Calcd
for C12H12O3S: C, 61.00; H, 5.12; S, 13.57. Found: C, 60.75;
H, 4.98; S, 12.38.
4.1.3. (E)-5,7-Dihydroxy-8-(2-methylbut-2-enoyl)-4-n-propyl-
2H-thiochromen-2-one (7)
A mixture of 6 (0.5 g, 2.11 mmol), AlCl3 (1.4 g, 10.59 mmol)
and CS2 (7 mL) was heated at 50 C while stirring for 30 min
PhNO2 (2 mL) was added dropwise and stirred for additional
30 min to get a homogeneous mixture. Tigloyl chloride
(0.262 g, 2.21 mmol) in PhNO2 (1 mL) was then added drop-
wise and the reaction mixture was stirred at 50 C for 24 h.
It was then cooled to room temperature and quenched with
crushed ice and dil. HCl before extracting with EtOAc
(3 · 30 mL). The combined organic layer was washed with
brine (3 · 20 mL), dried (Na2SO4) and concentrated. The resi-
due obtained was puriﬁed by column chromatography on silica
gel (EtOAc–pet-ether, 4:6) to furnish 7 (0.437 g, 65%) as a
brown solid. Mp 162–164 C: IR (CHCl3) 3263, 3019, 1720,
1610 cm1; 1H NMR (200 MHz, DMSO-d6) d 0.99 (t,
J= 7.2 Hz, 3H), 1.62 (m, 2H), 1.84 (d, J= 7.0 Hz, 3H),
1.87 (s, 3H), 3.04 (t, J= 7.5 Hz, 2H), 6.17 (s, 1H), 6.49 (q,
J = 7.0 Hz, 1H), 6.64 (s, 1H), 10.69 (s, 1H), 11.03 (s, 1H);
13C NMR (50 MHz, DMSO-d6) d 10.5, 14.0, 14.9, 24.1, 41.1,
102.1, 107.9, 117.4, 120.1, 137.9, 138.1, 142.4, 156.7, 158.4,
159.9, 181.6, 196.2; Anal. Calcd for C17H18O4S: C, 64.13; H,
5.70; S, 10.07. Found: C, 63.65; H, 5.58; S, 9.53.
4.1.4. 5-Hydroxy-8,9-dimethyl-4-n-propyl-8,9-
dihydrothiopyrano[2,3-f]chromene-2,10-dione (10)
To a solution of 7 (0.4 g, 1.25 mmol) in 2-butanone (5 mL),
anhydrous K2CO3 (0.520 g, 3.77 mmol) was added and the
mixture was reﬂuxed for 1.5 h. It was then cooled to room tem-
perature, acidiﬁed (pH 2) with dil. HCl and extracted with
EtOAc (3 · 20 mL). The combined organic layer was washed
with brine (3 · 10 mL), dried (Na2SO4) and concentrated.
The residue was chromatographed on silica gel column
(EtOAc–pet-ether, 3:7) to give a 1:1 mixture of isomeric chro-
manones 10 (0.360 g, 90%) as white solid, mp 243–245 C: IR
(Nujol) 3130, 3020, 1621 cm1; Anal. Calcd for C17H18O4S: C,
64.13; H, 5.70; S, 10.07. Found: C, 63.86; H, 5.72; S, 9.05.
4.1.5. 6,7-Dihydro-2H-1,5-dioxa-12-n-propyl-2,2,6,7-
tetramethyl-9-thia-triphenylene-8,10-dione (11 trans and 12 cis)
To a stirred solution of 10 (0.5 g, 1.57 mmol) in a mixture con-
taining 2-butanone: DMF (10 mL, 9:1), at room temperature,
anhydrous K2CO3 (0.65 g, 4.71 mmol), 3-chloro-3-methyl-1-
butyne (0.8 g, 7.85 mmol), n-Bu4NI (0.49 g, 1.22 mmol) were
added successively. The reaction mixture was heated at 60 C
for 1 h, and then anhydrous ZnCl2 (0.278 g, 2.04 mmol) was
added. The resultant mixture was further heated to 70 C for
20 h. It was cooled to room temperature and quenched with
saturated aq. solution of NH4Cl (3 mL) and extracted with
EtOAc (2 · 30 mL). The combined organic layer was washed
with brine (20 mL), dried (Na2SO4) and concentrated. The res-
idue obtained was puriﬁed through column chromatography
A synthesis of (±)-thia-calanolide A, its resolution and in vitro biological evaluation S1601on silica gel (230–400 mesh, EtOAc–pet-ether, 1:9) to afford
(±)-11 (0.132 g, 22%) as a white solid. Mp 143–144 C: IR
(CHCl3) 1670, 1627, 1201 cm
1; 1H NMR (200 MHz, CDCl3)
d 1.01 (t, J = 7.2 Hz, 3H), 1.22 (d, J = 6.9 Hz, 3H), 1.53 (d,
J = 6.5 Hz, 3H), 1.58 (s, 6H), 1.67 (m, 2H), 2.60 (m,
J = 6.8, 11.5 Hz, 1H), 2.98 (t, J = 7.2 Hz, 2H), 4.28 (dq,
J = 6.3, 11.5 Hz, 1H), 5.64 (d, J = 10.1 Hz, 1H), 6.37 (s,
1H), 6.67 (d, J = 10.1 Hz, 1H); 13C NMR (50 MHz, CDCl3)
d 10.2, 13.9, 19.5, 24.2, 27.7, 28.1, 42.0, 46.5, 78.8, 79.4,
107.5, 109.0, 112.9, 115.8, 123.9, 128.0, 143.9, 156.0, 158.3,
158.8, 186.3, 192.5; Anal. Calcd for C22H24O4S: C, 68.72; H,
6.29; S, 8.34. Found: C, 68.36; H, 6.32; S, 7.99; and (±)-
thia-calanolide D (±)-12 (0.072 g, 12%) as a syrup liquid;
IR (CHCl3) 1670, 1627, 1201 cm
1; 1H NMR (300 MHz,
CDCl3) d1.02 (t, J = 7.1 Hz, 3H), 1.20 (d, J = 7.3 Hz, 3H),
1.43 (d, J = 5.8 Hz, 3H), 1.56 (s, 6H), 1.64 (m, 2H), 2.70–
2.75 (m, J = 3.6, 7.3 Hz, 1H), 2.96 (t, J = 7.2 Hz, 2H), 4.70
(m, J = 2.9, 6.6 Hz, 1H), 5.65 (d, J = 9.5 Hz, 1H), 6.39 (d,
1H), 6.69 (d, J = 9.5 Hz, 1H); 13C NMR (75 MHz, CDCl3)
d 10.4, 13.9, 19.5, 24.3, 27.9, 28.2, 42.0, 46.7, 77.7, 78.9, 79.4,
96.1, 107.5, 116.0, 124.1, 127.9, 144.4, 155.7, 158.1, 158.8,
186.0, 192.1; Anal. Calcd for C22H24O4S: C, 68.72; H, 6.29;
S, 8.30. Found: C, 68.88; H, 6.33; S, 8. 29.
4.1.6. (±)-6,7-Dihydro-2H-1,5-dioxa-8-hydroxy-12-n-propyl-
2,2,6,7-tetramethyl-9-thia-triphenylene-10-one (3, 13)
To a solution of (±)-11 (0.020 g, 0.052 mmol) in EtOH (2 mL)
at 0 C, was added NaBH4 (0.003 g, 0.083 mmol) and the reac-
tion temperature was allowed to rise to 25 C over a period of
1 h. After completion of the reaction 2–3 drops of water were
added and the reaction mixture was extracted with EtOAC
(3 · 3 mL), the combined organic layer was washed with brine,
dried with Na2SO4 and concentrated. The residue obtained
was puriﬁed through ﬂash column chromatography (EtOAc–
pet-ether, 2:8) to give (±)-thia-calanolide A (±)-3 (0.009 g,
44%) as a white solid. Mp 158–160 C: IR (CHCl3) 3410,
1619, 1215 cm1; 1H NMR (200 MHz, CDCl3) d 1.01 (t,
J = 7.3 Hz, 3H), 1.12 (d, J = 7 Hz, 3H), 1.48 (d,
J = 6.8 Hz, 3H), 1.52 (s, 6H), 1.64 (m, 2H), 2.05 (sext,
J = 6, 13.4 Hz, 1H), 3.01 (dq, 3.4, 8.0, 2H), 4.02 (quin,
J = 6.6, 13.1 Hz, 1H), 4.55 (d, J = 5.9 Hz, 1H), 5.60 (d,
J = 9.9 Hz, 1H,), 6.3 (s, 1H), 6.66 (d, J = 9.9 Hz, 1H); 13C
NMR (CDCl3, 75 MHz, d 14.0, 15.9, 19.2, 24.5, 27.5, 27.9,
41.7, 42.1, 68.2, 77.8, 108.9, 112.0, 112.7, 116.8, 122.5, 128.0,
140.9, 151.5, 153.3, 157.9, 183.6; 13C NMR (75 MHz, Ace-
tone-d6) d 14.5, 15.9, 19.7, 25.6, 27.7, 28.3, 42.8, 43.6, 69.0,
77.7, 78.8, 109.7, 112.5, 115.0, 117.6, 123.4, 129.4, 142.5,
153.7, 154.0, 157.9, 184.2. Anal. Calcd for C22H26O4S: C,
68.37; H, 6.78; S, 8.30. Found: C, 68.81; H, 6.87; S, 8.03;
and (±)-thia-calanolide B (±)-13 (0.003 g, 14%) as a white so-
lid mp 156–158 C: IR (CHCl3) 3400, 1621, 1533, 1122 cm1;
1H NMR (200 MHz, CDCl3) d 1.03 (t, J = 7.2 Hz, 3H), 1.22
(d, J = 6.9 Hz, 3H), 1.41 (d, J = 6.3 Hz, 3H), 1.49 (s, 6H),
1.65 (m, 2H), 2.30 (m, J = 5.8,12.7 Hz, 1H), 3.01 (m, 2H),
4.49 (m, J = 6.8, 13.7 Hz, 1H), 4.82 (d, J = 6 Hz, 1H), 5.63
(d, J = 9.8 Hz, 1H), 6.31 (s, 1H), 6.70 (d, J = 9.8 Hz, 1H).
4.1.7. (±)-6,7-Dihydro-2H-1,5-dioxa-8-hydroxy-12-n- propyl-
2,2,6,7-tetramethyl-9-thia-triphenylene-10-one (14)
To a solution of 12 (0.050 g, 0.13 mmol) in EtOH (5 mL) at
0 C was added NaBH4 (0.009 g, 0.26 mmol) while stirringand the temperature was allowed to rise to 30 C and the mix-
ture was stirred further for 1 h. After completion of reaction,
ice water (1 mL) was added and the reaction mixture was ex-
tracted with EtOAc (3 · 5 mL). The combined organic layer
was washed with brine (5 mL), dried (Na2SO4) and concen-
trated. The residue obtained was puriﬁed through ﬂash column
chromatography on silica gel (230–400 mesh, EtOAc–pet-
ether, 2:8) to give (±)-14 (0.036 g, 71%) as a white solid.
Mp 167–168 C: IR (CHCl3) 3400, 1619, 1201 cm1; 1H
NMR (300 MHz, CDCl3) d 1.01 (t, J = 7.3 Hz, 3H), 1.21 (d,
J = 7.3 Hz, 3H), 1.53 (d, J = 6.5 Hz, 3H), 1.55 (s, 3H), 1.58
(s, 6H), 1.67 (m, 2H), 2.62 (m, 1H), 3.46 (m, 2H), 4.28 (m,
J = 2.2, 6.6 Hz, 1H), 4.79 (d, J = 3.6 Hz, 1H), 5.67 (d,
J = 9.5 Hz, 1H), 6.37 (d, 1H), 6.70 (d, J = 9.5 Hz, 1H). Anal.
Calcd for C22H26O4S: C, 68.37; H, 6.78; S, 8.30. Found: C,
68.65; H, 6.91; S, 8.44.Acknowledgments
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